Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC by Francesca Lucibello, MD, Valérie Gounant, MD, PhD, Mihaela Aldea, MD, PhD, Michaël Duruisseaux, MD, PhD, Maurice Perol, MD, Christos Chouaid, MD, Jaafar Bennouna, MD, PhD, Vincent Fallet, MD, Aldo Renault, MD, Florian Guisier, MD, PhD, Etienne Giroux-Leprieur, MD, PhD, Marie Wislez, MD, PhD, Anne-Claire Toffart, MD, PhD, Julien Mazieres, MD, PhD, Clémence Basse, MD, PhD, Nadia Hegarat, PhD, Matthieu Carton, MD, Nicolas Girard, MD, PhD

“…We also observe the aggressive nature of disease progression, frequent utilization of chemotherapy and antiangiogenic agents as initial subsequent therapies, and limited insight into resistance mechanisms due to infrequent rebiopsy and genomic profiling at progression.…”
Get full text

Protein kinase inhibitors as targeted therapy for glioblastoma: a meta-analysis of randomized controlled clinical trials by José Pinto-Fraga, Celia García-Chico, Simone Lista, Pedro Miguel Lacal, Giuseppe Carpenzano, Maurizio Salvati, Alejandro Santos-Lozano, Grazia Graziani, Claudia Ceci

“…The standard treatment for newly diagnosed GBM includes surgical resection, when feasible, followed by radiotherapy and temozolomide-based chemotherapy. Upon disease progression, the anti-vascular endothelial growth factor-A (VEGF-A) monoclonal antibody bevacizumab, can be considered.Given the limited efficacy of pharmacological treatments, particularly for the recurrent disease, several molecularly targeted interventions have been explored, such as small-molecule protein kinase inhibitors (PKIs), inhibiting tyrosine kinase growth factor receptors and downstream signaling pathways involved in GBM angiogenesis and infiltrative behavior.This meta-analysis, based on searches in PubMed and Web Of Science, evaluated 12 randomized controlled trials (RCTs) examining PKIs in patients with newly diagnosed or recurrent GBM. …”
Get full text

IFN-γ reprograms cardiac microvascular endothelial cells to mediate doxorubicin transport and influences the sensitivity of mice to doxorubicin-induced cardiotoxicity by Haoyu Ji, Wenya Ma, Xu Liu, Hongyang Chen, Yining Liu, Zhongyu Ren, Daohong Yin, Ao Cai, Zizhen Zhang, Xin Wang, Wei Huang, Leping Shi, Yanan Tian, Yang Yu, Xiuxiu Wang, Yang Li, Yu Liu, Benzhi Cai

“…Abstract Doxorubicin (DOX) is a first-line chemotherapy agent known for its cardiac toxicity. DOX-induced cardiotoxicity (DIC) severely limits the use for treating malignant tumors and is associated with a poor prognosis. …”
Get full text

plaTform fOr Urinary tract infection diagnostiC evAluatioN (TOUCAN): a protocol for a prospective diagnostic accuracy study of point-of-care testing in patients suspected of acute... by Thomas R Fanshawe, Philip J Turner, Gail N Hayward, Margaret Glogowska, Alastair D Hay, Michael Moore, Mark Lown, Christopher C Butler, Mandy Wootton, Mark H Wilcox, Jane Freeman, Nicola Kenealy, Valerie Tate, Owain Llion, Rebecca Lowe

Get full text

Oncolytic influenza virus enhances killing effect of gemcitabine against pancreatic cancer cells by MENG Zihe, MENG Zihe, XU Yongru, DENG Zhaoda

“…Objective‍　‍To investigate the killing effect of the recombinant oncolytic influenza virus OvFlu-GM-CSF， constructed using reverse genetics （RG） technology， in combination with chemotherapy drug， gemcitabine （GEM）， against pancreatic cancer cells. …”
Get full text

Relationship between neutropenia caused by nanoliposomal irinotecan/fluorouracil/leucovorin and treatment outcomes in the NAPOLEON-2 study (NN-2301) by Tomonori Araki, Yuki Sonoda, Mototsugu Shimokawa, Taiga Otsuka, Kohei Hayashi, Takuya Honda, Kazuhiko Nakao, Taro Shibuki, Junichi Nakazawa, Shiho Arima, Keisuke Miwa, Yoshinobu Okabe, Futa Koga, Yujiro Ueda, Yoshihito Kubotsu, Hozumi Shimokawa, Shigeyuki Takeshita, Azusa Komori, Kazuo Nishikawa, Satoshi Otsu, Ayumu Hosokawa, Hisanobu Oda, Tatsunori Sakai, Shuji Arita, Machiko Kawahira, Hiroki Taguchi, Kengo Tsuneyoshi, Yasunori Kawaguchi, Toshihiro Fujita, Takahiro Sakae, Tsuyoshi Shirakawa, Toshihiko Mizuta, Kenji Mitsugi

Get full text

Study Protocol of the Korean EGFR Registry: A Multicenter Prospective and Retrospective Cohort Study in Nonsmall Cell Lung Cancer Patients With EGFR Mutation by Chang Dong Yeo, Dong Won Park, Seong Hoon Yoon, Eun Young Kim, Jeong Eun Lee, Shin Yup Lee, Chang‐Min Choi, In‐Jae Oh, Do Jin Kim, Jeong Seon Ryu, Jae Cheol Lee, Young‐Chul Kim, Tae Won Jang, Kye Young Lee, Seung Hun Jang, Seung Joon Kim, for the Korean EGFR Registry Investigators

“…The primary endpoint is disease‐free survival in patients who have undergone radical therapy (surgery and radiotherapy) or progression‐free survival in those receiving targeted therapy (first, second, and subsequent lines), chemotherapy (first and subsequent lines), combination therapy, and palliative/maintenance therapy according to stages of EGFR‐mutated NSCLC. …”
Get full text

Safety and efficacy of trifluridine/tipiracil +/− bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial by Marion Thibaudin, Nicolas Roussot, Chloé Burlot, Antonin Schmitt, Julie Vincent, Zoé Tharin, Leila Bengrine, Hélène Bellio, Aurélie Bertaut, Léa Hampe, Susy Daumoine, Emilie Rederstorff, Morgane Peroz, Titouan Huppe, Valentin Derangère, David Rageot, John Simard, Caroline Truntzer, Jean David Fumet, Francois Ghiringhelli

“…The combination of XB2001 with FTD/TPI and bevacizumab is feasible and safe, and showed encouraging clinical activity in chemotherapy-resistant mCRC.…”
Get full text

Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50% by Yoshihito Kogure, MD, PhD, Hiroya Hashimoto, PhD, Haruko Daga, MD, PhD, Yasushi Fukuda, MD, Akihiro Bessho, MD, PhD, Tadaaki Yamada, MD, PhD, Yukihiro Toi, MD, Tomoki Kimura, MD, PhD, Hiroshige Yoshioka, MD, PhD, Koichi Azuma, MD, PhD, Naoki Furuya, MD, PhD, Yasutaka Fukui, MD, PhD, Akiko M. Saito, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Hideo Saka, MD, Masashi Kondo, MD, PhD

“…Eligible participants had metastatic or recurrent nonsquamous NSCLC without sensitizing EGFR or ALK alterations, were aged 75 years or above, had a programmed cell death-ligand 1 tumor proportion score of less than 50%, had not undergone systemic chemotherapy, and had an Eastern Cooperative Oncology Group performance status of 0 or 1. …”
Get full text

Real-world ePRO use and clinical outcomes using electronic patient-reported symptom monitoring for patients with advanced non-small-cell lung cancer receiving first-line pembrolizu... by L. Johnetta Blakely, Sabine Oskar, Ian Kudel, Ashley Roush, Zoya Shamsi, Toni Perry, Annette Christianson, Brittni Smith, Thomas Burke

“…Methods: Adults with advanced NSCLC, ECOG performance status of 0–2, who received first-line (1L) pembrolizumab (monotherapy or with chemotherapy) were eligible. Those initiating pembrolizumab from 1 July 2017 to 30 June 2019, identified retrospectively (historical cohort), were compared with those initiating pembrolizumab from 1 October 2019 to 30 September 2021 who were prospectively offered Noona (standard of care [SoC] cohort). …”

Shaoyao Gancao decoction alleviates paclitaxel-induced cognitive impairment by activating PTEN/PI3K/AKT pathway to inhibit NETs formation by Xu Ying, Su Yue, Hu Yuwen, Li Xiang, Zhou Ziyan, Yuan Ningning, Ji Xiaowei, Jiang Ruoyu, Wang Wenzhu, Zhang Yafeng, Zhai Guojie, Cheng Xiaolan

“…Purpose: Paclitaxel-induced cognitive impairment (PICI) is a frequent and severe adverse reaction of chemotherapy. Increased neuroinflammation related to neutrophil extracellular traps (NETs) may play a key role in PICI. …”
Get full text

Smad1 Promotes Tumorigenicity and Chemoresistance of Glioblastoma by Sequestering p300 From p53 by Lingli Gong, Daxing Xu, Kaixiang Ni, Jie Li, Wei Mao, Bo Zhang, Zhening Pu, Xiangming Fang, Ying Yin, Li Ji, Jingjing Wang, Yaling Hu, Jiao Meng, Rui Zhang, Jiantong Jiao, Jian Zou

“…This results in enhanced tumor growth and resistance to chemotherapy, particularly in tumors with missense mutant p53. …”
Get full text

Assessment of prognosis and responsiveness to immunotherapy in colorectal cancer patients based on the level of immune cell infiltration by Kaili Liao, Minqi Zhu, Lei Guo, Zijun Gao, Jinting Cheng, Bing Sun, Yihui Qian, Bingying Lin, Jingyan Zhang, Tingyi Qian, Yixin Jiang, Yanmei Xu, Qionghui Zhong, Xiaozhong Wang

“…Furthermore, we identified distinct chemotherapy responses to 39 drugs between these risk subgroups.ConclusionThis study revealed a significant correlation between high levels of immune infiltration and unfavorable prognosis in patients with colon cancer. …”
Get full text

KiKli Fit: Insights into the Development and Practice of a Physical Activity Program in Pediatric Cancer by Lisa Hillebrech, Lars Rehbein, Ann Christin Schneider, Sara Müller, Christina Schindera, Katharina Eva, Valentin Benzing

“…However, they identified several barriers to participation, including medical constraints, chemotherapy administration, fatigue, visits, or lack of motivation. …”
Get full text

Metabolic reprogramming and immunological changes in the microenvironment of esophageal cancer: future directions and prospects by Zhi-Xun Guo, Jia-Li Ma, Jin-Qiu Zhang, Ling-Ling Yan, Ying Zhou, Xin-li Mao, Xin-li Mao, Xin-li Mao, Shao-Wei Li, Shao-Wei Li, Shao-Wei Li, Xian-Bin Zhou, Xian-Bin Zhou, Xian-Bin Zhou

“…Current treatment modalities for esophageal cancer primarily include encompass chemotherapy and a limited array of targeted therapies, which are hampered by toxicity and drug resistance issues. …”
Get full text

Treatment of Helicobacter pylori infection: mainstream and innovations (Review of the literature and Russian gastroenterological association Advisory council resolution, May 19, 20... by V. T. Ivashkin, I. V. Mayev, T. L. Lapina, A. A. Sheptulin, A. S. Trukhmanov, R. A. Abdulkhakov, S. A. Alekseyenko, N. N. Dekhnich, R. S. Kozlov, I. L. Klyaritskaya, S. A. Kurilovich, M. F. Osipenko, V. I. Simanenkov, I. B. Khlynov

Get full text

Cardiovascular disease risk in cancer survivors: a population-based cohort study from the UK Biobank, and meta-analysis of cohort studies by Hong Li, Yazhou He, Zubing Mei, Hong Wu, Yang Shen, Ziqiang Wang, Jichun Zhao, Chuan Xu, Yanhong Zhou, Chi Shu, Botao Yu, Xiran Wang, Changtao Li, Yiqiang Liu

“…Evidence appraisal identified one convincing association between hematologic/lymphatic malignancies and ischaemic heart disease, along with 29 highly suggestive associations.Conclusions Our study provided comprehensive estimates of CVD incidence in cancer survivors and identified a significantly elevated CVD risk among patients with cancer, regardless of chemotherapy or radiotherapy. These findings underscore the need for routine assessment of CVD risk factors at cancer diagnosis to enhance the well-being and survival of patients with cancer.PROSPERO registration numberCRD42022307056…”
Get full text

PET/CT-derived coronary calcium score may predict cardiac complications in anthracycline-treated patients with lymphoma by Genevieve Douglas, Zoe Loh, Evonne S.Y. Shum, Sze-Ting Lee, Niamh Waters, Garry Hamilton, Geoffrey Chong, Alexandra C. Murphy, Eliza A. Hawkes

“…Our study aimed to evaluate whether CACS obtained from pretreatment positron emission tomography (PET)/computed tomography (CT) scans could stratify cardiac event risk in patients with lymphoma receiving anthracycline-based chemotherapy. We enrolled 358 consecutive patients with lymphoma treated between 2012 and 2022, calculating the CACS from their pretreatment PET/CT. …”
Get full text

Evaluating the radiosensitivity of the oral microbiome to predict radiation-induced mucositis in head and neck cancer patients: A prospective trial by Andreas R. Thomsen, Elsa Beatriz Monroy Ordonez, Michael Henke, Benedikt Luka, Jörg Sahlmann, Henning Schäfer, Vivek Verma, Nadine Schlueter, Anca-Ligia Grosu, Tanja Sprave

“…The vast majority of patients received adjuvant RT and concurrent chemotherapy. Overall, 34 (58.6 %) participants developed grade 3 OM after a median dose of 32 Gy. …”
Get full text

Natural Product Identification and Molecular Docking Studies of Leishmania Major Pteridine Reductase Inhibitors by Moses N. Arthur, George Hanson, Emmanuel Broni, Patrick O. Sakyi, Henrietta Mensah-Brown, Whelton A. Miller, Samuel K. Kwofie

“…This enzyme catalyzes the NADPH-dependent reduction of pterins to their tetrahydro forms. While chemotherapy remains the primary treatment, its effectiveness is constrained by drug resistance, unfavorable side effects, and substantial associated costs. …”
Get full text